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Abstract Driven by the rising popularity of minimally
invasive techniques, the demand for cosmetic procedures is
increasing. Cosmetic body-shaping procedures can be cate-
gorized into those that remove tissue and those that add
volume.Thisreviewfocusesonthelatterofthesecategories,
particularly on the use of resorbable hyaluronic acid gels
speciﬁcally developed for minimally invasive volume
enhancement. Pilot studies of hyaluronic acid involving its
injection to contour various body deformities and its recent
use in female breast augmentation are discussed. Injectable
hyaluronic acid is effective and well tolerated. It represents
an attractive treatment option for volume restoration or
augmentation by providing predictable long-lasting results
after minimally invasive administration. Alternative treat-
ment options for volume enhancement also are summarized
including fat transfer, silicone implants, and the use of
injectable nonresorbable products such as silicone, poly-
alkylimide,andpolyacrylamidegels.Aspatientscontinueto
opt for nonsurgical procedures that offer predictable results,
the development of minimally invasive products such as
hyaluronic acid is increasingly important.
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The skills developed to treat injuries sustained during
World War II currently are applied extensively to those
born in subsequent decades. ‘‘Baby boomers,’’ individuals
born in the 1940s, 1950s, and early 1960s, are increasingly
turning to cosmetic surgery to improve their appearance. In
the United States, individuals 40 years of age or older
comprise 71% of all the patients who underwent cosmetic
surgery during 2006 [3].
In 2006 compared with 2005, patients ages 40-54 years
and 55 years or older respectively underwent 9% and 8%
more cosmetic procedures. However, the rise in demand for
cosmetic surgery procedures is not limited to older groups.
Indeed, in 2007, the single greatest increase in demand for
procedures was among those 20 to 29 years of age [3].
Conﬁrming the interest in aesthetic interventions shown by
younger groups despite their possession and advantage of
‘‘youth,’’22%ofallcosmeticproceduresundertakenin2006
were performed for those 19 to 34 years of age [2]. The rise
in minimally invasive cosmetic procedures has driven the
overall growth in cosmetic surgery [2, 3].
This review focuses on the use of hyaluronic acid for
body contouring and breast augmentation. It also brieﬂy
discusses the range of alternative treatment options for
body reshaping (summarized in Table 1).
Hyaluronic Acid
Stabilized hyaluronic acid of nonanimal origin (NASHA
TM
gel; Q-Med AB, Uppsala, Sweden) was developed using
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DOI 10.1007/s00266-008-9303-yTable 1 Summary of advantages and disadvantages of procedures/products used to create volume in the body
Intervention Advantages Disadvantages
Autologous procedures
Injectable fat Potential for lasting durability Unpredictability of cosmetic results
Versatile (can be used for a wide variety of indications) Unpredictability of fat survival
Can be used in combination with liposuction to sculpt body Donor site morbidity
Filler completely biocompatible Time consuming process
Potential to regenerate surrounding tissues
Segmental fat
transfer
Long-lasting graft survival Requires appropriate donor site, so not suitable
for many indications
Donor site subject to considerable morbidity and
scarring
Time-consuming, complex procedure
Requires general anaesthesia
Extensive downtime
Costly
Flap surgery Long-lasting graft survival Requires appropriate donor site, so not suitable
for many indications
Donor site subject to considerable morbidity and
scarring
Time-consuming, complex procedure
Requires general anaesthesia
Extensive downtime
Costly
Allogeneous procedures
Silicone
implants
Very long-lasting correction Risk of rupture and other serious side effects
No donor site required Not suitable to correct small concavities
Can be used to create substantial volume More downtime required compared with
minimally invasive procedures
Less downtime involved compared with ﬂap surgery More costly than minimally invasive procedures
Less complex and time-consuming compared with ﬂap surgery
Injectable
silicone
Long-lasting correction Questionable long-term safety
Requires no donor site Little empirical evidence regarding safety and
efﬁcacy in the peer-reviewed literature
Minimally invasive: little downtime, use of general anaesthetic not required,
can be carried out in an ofﬁce environment, quick, relatively inexpensive
Cannot be used to create larger volumes in the
body
Polyalkylimide
gel
Long-lasting correction Questionable long-term safety
Requires no donor site Little empirical evidence regarding safety
and efﬁcacy in the peer-reviewed literature Minimally invasive: little downtime, use of general anaesthetic not required,
can be carried out in an ofﬁce environment, quick, relatively inexpensive
Versatile
Polyacrylamide
gel
Long-lasting correction Questionable long-term safety
Requires no donor site Little empirical evidence regarding safety and
efﬁcacy in the peer-reviewed literature Minimally invasive: little downtime, use of general anaesthetic not required,
can be carried out in an ofﬁce environment, quick, relatively inexpensive
Versatile
Macrolane
TM
VRF
Requires no donor site Correction is not permanent
Minimally invasive: little downtime, use of general anaesthetic not required,
can be carried out in an ofﬁce environment, quick, relatively inexpensive
NASHA
TM gels used in facial rejuvenation associated with a solid safety
record
Versatile
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123patented technology. A number of NASHA-based prod-
ucts, approved by the Food and Drug Administration
(FDA), have been studied extensively for facial tissue
augmentation in both the United States and Europe [5, 6,
10, 15, 16, 36].
Hyaluronic acid, a naturally occurring polysaccharide,
is a ubiquitous component of all mammalian connective
tissues [20]. The chemical structure of hyaluronic acid is
consistent across species, so potential for immunologic
reactions is minimal when hyaluronic acid is used as a
skin ﬁller [31]. As hyaluronic acid is naturally and
gradually degraded, the potential problems associated
with permanent ﬁllers, such as the permanency of
incorrect injections or technical errors, are not applica-
ble. Hyaluronic acid can be removed easily with the use
of hyaluronidase.
To address the need for an injectable, biocompatible,
and resorbable ﬁller to enhance body contours, a new
NASHA-based medical implant, Macrolane
TM (Q-Med
AB), was developed and approved in Europe in 2006. More
recently, two improved versions of Macrolane with two
different volume restoration factors (VRF) that have
broader indications, Macrolane VRF20 and VRF30, have
received CE marks. These novel products are indicated for
volume restoration and contouring of body surfaces.
Whereas VRF30 is intended primarily for deep subcuta-
neous administration, VRF20 (a thinner NASHA gel) is
intended for more superﬁcial subcutaneous injection.
A nonrandomized, open-label pilot study was conducted
recently to explore the efﬁcacy, duration of effect, and
tolerability of the initial Macrolane formulation for rec-
ontouring body deformities of different etiologies
(irregularities after liposuction and scars arising from
trauma or surgery). The study was approved by the ethical
committee at the Karolinska Institute in Stockholm. Using
a 12-gauge cannula, Macrolane was injected supraperios-
tally and/or into the subcutaneous fatty tissue, then spread
into the area to be augmented. Patients initially were
treated with Macrolane (B20 ml), with an optional ‘‘touch-
up’’ treatment given 4 weeks later.
An example of a concave deformity correction using
Macrolane is illustrated in Fig. 1. Efﬁcacy was assessed
independently by patients and investigators at 4 weeks,
then 3, 6, 9, and 12 months after the last treatment using
the Global Esthetic Improvement Scale (GEIS). The
proportion of patients rated as improved (somewhat
improved, moderately improved, or very much improved)
was calculated using the ‘‘intention-to-treat’’ approach in
an ‘‘observed case’’ manner (i.e., no imputations were
made for missing data).
Of the 56 patients recruited, 46 completed the study.
The patients initially received a mean Macrolane volume of
16.6 ± 8.5 ml. ‘‘Touch-up’’ treatment was performed for
16 of the 56 patients, who received a mean gel volume of
14.7 ± 4.9 ml. The proportions of improved patients, as
assessed by the study investigators, were 87% at 4 weeks,
Fig. 1 Correction of a body
concave deformity by
Macrolane injection. a Patient
before treatment. b Patient
3 months after treatment
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123then 85% at 3 months, 69% at 6 months, 75% at 9 months,
and 52% at 12 months (Table 2). The corresponding rates,
as assessed by the patients, were 81%, 80%, 69%, 70%,
and 57% (Fig. 2).
No serious adverse events were reported, and the
majority of treatment-related adverse events (58/69) were
mild to moderate in intensity and transient in nature. The
most commonly reported treatment-related adverse events
were anticipated postinjection reactions such as injection-
site pain (17 events) and injection-site reactions (swelling,
tenderness, and/or redness; 13 events). These events typi-
cally occurred after injection, were of mild to moderate
intensity, and resolved within 3 weeks. Six instances of
fever also occurred, beginning at most 1 day after treat-
ment and lasting 2 to 6 days. Antibiotics were used to treat
these cases.
The potential use of Macrolane also was explored by the
authors in an open multicenter pilot study approved by the
appropriate ethical committee (Karolinska Institute,
Stockholm, Sweden) and designed to evaluate the treat-
ment procedure, safety, and efﬁcacy of NASHA for female
breast augmentation. Nonpregnant, non–breast-feeding
women aged 25 to 40 years with small breasts and seeking
small-to-moderate augmentation were included in the
study. Macrolane was injected at a level anterior to the
pectoralis major muscle and posterior to the mammary
gland using a 12-gauge needle. All the patients underwent
clinical examinations, magnetic resonance imaging (MRI),
mammography, and ultrasound scans. The patients were
followed up for 48 months, and data from this period
currently are being evaluated.
At the initial treatment session, 19 patients were injected
with 80 to 100 ml of Macrolane per breast. Seven patients
received touch-up treatment (20 ml) for a total of 12
breasts. The mean total volume injected per patient, in both
breasts, was 211 ml (range, 180–240 ml). The investigator-
assessed GEIS indicated that an aesthetic improvement was
obtained for 97% of the breasts at months 1 and 3, for
100% at month 6, for 76% at month 12, 74% at month 18,
and 47% at month 24. Figure 3 illustrates an example of
breast augmentation after Macrolane injection.
The most commonly reported adverse events were
anticipated postinjection reactions such as injection-site
pain (29 events) and injection-site reactions (18 events),
described as swelling, redness, or hardness. These events
typically were of mild to moderate intensity and persisted
for up to 2 weeks. The most commonly reported cosmetic
adverse events were implant palpability and nodules. Two
patients had the implant removed: one due to capsular
contraction and one due to inﬂammatory symptoms.
Importantly, the injected material was easily removable by
aspiration. A simple remedy for capsule formation was the
use of external manipulation (closed capsulotomy). This
old and abandoned technique for correcting capsules
around silicone implants is far more acceptable with
hyaluronic acid because this naturally occurring substance
will be gradually absorbed. A total of ﬁve patients expe-
rienced inﬂammatory symptoms with onset 13 to 47 days
after injection. These events were unexpected, and the
Table 2 Improvement of body
shape after hyaluronic acid
(HA) injection, as assessed by
the investigator and patients,
using the Global Esthetic
Improvement Scale (GEIS)
Time after HA
injection
Proportion of patients (%)
Somewhat
improved
Moderately
improved
Very much
improved
Investigator-assessed 4 weeks 13.2 24.5 49.1
3 months 23.6 36.4 25.5
6 months 26.9 26.9 15.4
9 months 38.6 25.0 11.4
12 months 23.9 23.9 4.3
Patient-assessed 4 weeks 20.8 28.3 32.1
3 months 29.1 27.3 23.6
6 months 38.5 13.5 17.3
9 months 38.6 15.9 15.9
12 months 28.3 21.7 6.5
Fig. 2 Proportion of improved patients after treatment with Macro-
lane, as assessed by both patients and investigators
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123reason for the accompanying fever was unclear. All cases
resolved within 1 week, either spontaneously or after
treatment with antibiotics and/or nonsteroidal antiinﬂam-
matory drugs [38].
In summary, Macrolane gave satisfactory cosmetic
results for at least 18 months for the majority of breasts
treated. However, reﬁnement of the gel and an improved
implantation technique would enhance the efﬁcacy and
safety of the product. Most importantly, MRI and
mammography did not show any morphologic alterations
in the gland during and after absorption of hyaluronic
acid. No cases of microcalciﬁcation were observed. The
investigators (Tengvar M et al. [42]) also determined that
it was considerably easier to interpret the results of
mammography than those obtained with silicone or sal-
ine breast implant surgery. The injected hyaluronic acid
gel was visible 12 months after treatment in the mam-
mograms of all ﬁve patients who had follow-up
mammography (i.e., only those older than 35 years).
Mammograms from two representative patients (both
breasts) are shown in Fig. 4. In two of the patients, the
gel was located deeply and partly within the pectoralis
muscle. In all cases, the gel was partially superimposed
over the glandular tissue.
Fig. 3 Breast augmentation by
Macrolane injection. a Before
treatment. b Three months after
treatment. c Six months after
treatment
Fig. 4 Mammograms
(mediolateral oblique
projection) at 12 months from
two representative study
participants. The arrows
indicate the location of the
implanted hyaluronic acid gel
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123Other Treatment Options
Fat Transfer
With the advent of liposuction, plastic surgeons were
afforded a valuable by-product, namely semiliquid fat, that
could be implanted with relative ease using a needle or
small cannula [12, 19, 22, 24, 27]. Autologous fat transfer
is intuitively appealing. The material is completely bio-
compatible, requires no pretesting, and usually is available
in ample quantities [12]. Implanted fat can be removed if
required yet also has the potential to be permanent.
Because the ability to remove fat from sites of excess and
to implant it into sites of deﬁciency allows the body to be
sculpted, fat grafting has become increasingly popular. The
prospective use of adipose tissue stem cells in tissue reju-
venation after implantation also has been investigated
recently [30, 34].
However, fat grafting is not without its disadvantages.
Infection is always possible with surgical procedures, and
damage to local nerves, muscles, glands, and blood vessels
is a possibility during harvesting. Compared with alloge-
neous injectable products, the procedure is time consuming
and expensive, with unpredictable efﬁcacy, and often is
associated with pronounced swelling of the recipient tis-
sues. A number of studies also have reported disappointing
long-term survival rates for implanted fat, relatively low
rates for long-term patient satisfaction, and excessive
growth of the transplanted fat [12, 18, 25, 32]. Further-
more, fundamental questions remain regarding the optimal
harvesting site, processing technique, and most effective
injection technique [9].
Free fat grafts have been used successfully to create
volume in facial, reconstructive, and cosmetic surgery [14,
29]. A recent retrospective study of fat transplantation to
the buttocks and legs showed that fat grafts were able to
live and persist in patients, growing if the patient gained
weight in the implanted area and not losing circumference
when weight was lost [14]. The longevity of results
achieved with free fat grafts is the principal advantage of
the procedure. Transplanting a segment of fat causes less
trauma to the graft and allows blood vessels to remain
intact within the fat graft. Moreover, studies indicate
reduced tissue loss and improved graft survival. However,
free fat grafts require an appropriate donor site and are not
suitable for many patients or indications. Furthermore,
segmental fat transfer requires donor- and recipient-site
incisions and has the potential for scar visibility [22]. The
procedure is more time consuming and costly than inject-
able fat transfer, so it is not generally performed for purely
cosmetic reasons.
Flap Surgery
Flap surgery can be used to create substantial volume for
areasofdeﬁciency,usuallythosearisingfromtrauma(injury
or surgery), tumor removal, and burns [4, 23]. For example,
in breast reconstruction, the latissimus dorsi muscle ﬂap can
be used without signiﬁcant loss of function. It can be moved
into the breast defect while still attached to its blood supply
under the axilla. Flap surgery often involves complex pro-
cedures associated with donor-site morbidity and
considerable scarring, which are highly signiﬁcant draw-
backs to such surgery. It is therefore not an appropriate
option for patients considering a procedure to create modest
amounts of volume for purely aesthetic improvement.
Silicone Implants
The placement of silicone implants can provide long-last-
ing correction and substantial volume, hence their
widespread use for breast augmentation. However, as with
any invasive procedure, complications after implant sur-
gery are not uncommon. It also is important to note that
irrespective of how the implant is constructed or the
hardness of the gel used, reoperation can be expected in a
relatively large proportion of cases. Recent reports indicate
that the risk of complications within the 3-year period after
implantation is as high as 50% with some silicone implants
[13]. Generally, silicone implants are not useful for cor-
recting smaller concavities such as irregularities after
liposuction or small scars.
Injectable Silicone
Use of medical grade silicone to repair complicated retinal
detachmentsisapprovedbytheregulatoryauthoritiesinboth
the United States and the European Union. Its off-label use
forcosmeticpurposesalsohasbeenexplored[8].Injectionof
silicone elicits a chronic inﬂammatory reaction, with giant
cell formation and encapsulation of the injected product in
ﬁbrous tissue, thereby creating volume [17].
The use of injectable silicone has been hampered by
adverseeffectssuchasinfection,palpablenoduleformation,
granuloma formation, migration, and silicone embolism
[17]. However, its proponents claim that it is easy to use,
long-lasting, and low in cost, and that high rates of compli-
cations usually are associated with the improper use of
industrial grade silicone injected by unlicensed or unskilled
practitioners[35].Nevertheless,reportsinthepeer-reviewed
literature to support its use for correction of large-scale
volume deﬁciencies in the body are lacking.
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Polyalkylimide gel (Bio-Alcamid; Polymekon Laborato-
ries, Italy) received a CE mark in 2001 for use to create
volume in both the face and body for cosmetic purposes. A
recent review stated that the product is biocompatible, is
easy to inject and remove, does not migrate, and can be
used for correction of slight to very serious aesthetic
defects [11, 39]. However, despite these suggestions, Bio-
Alcamid does not currently have FDA approval.
The gel has been used to repair muscular defects after
trauma, to augment the buttocks, and to correct postpo-
liomyelitis amyotrophy of the calves and pectus excavatum
as well as irregularities after liposculpture and scar
depressions [11]. It also has been used for a wide range of
cosmetic defects of both the face and body, with high
levels of patient satisfaction reported [28]. However, given
the potential permanency of the gel and various reports of
serious complications such as granuloma formation [21],
long-term studies of the agent are required to conﬁrm its
safety and efﬁcacy.
Polyacrylamide Gel
Polyacrylamide hydrogel is a nonresorbable sterile
‘‘watery’’ injectable gel (Aquamid; Contura, Soeborg,
Denmark). Aquamid received its CE mark for soft tissue
facial augmentation and corrections in 2001, which was
extended in 2003 to include soft tissue corrections of the
body. However, Aquamid does not currently have FDA
approval. High rates of patient satisfaction have been
reported for Aquamid treatment of facial contour defor-
mities or soft tissue deﬁciencies caused by aging, acne,
trauma, and surgery [43]. However, no studies on the safety
and efﬁcacy of this treatment for body contour deformities
have been published.
Polymethylmethacrylate
Artecoll (Artes Medical Inc., San Diego, USA),
composed of nonbiodegradeable polymethylmethyacrylate
particles and bovine collagen, generally is recommended
for use in the face. After deep dermal injection, the
bovine collagen is broken down and replaced by
endogenous collagen. Renamed Arteﬁll, the product
achieved FDA approval in 2006, although 21% of
patients injected in the registration study experienced
adverse events [7] and incidences of late-onset granu-
loma formation have been reported [1, 41]. Skin testing
also is required with Arteﬁll because the collagen in the
product is of animal origin.
Discussion
The skilled plastic surgeon has a wide range of techniques
and products available to create volume in the body.
Although the type of defect in question very often limits
the selection of interventions available, it is a reasonable
assumption that where possible, patients prefer minimally
invasive procedures over more drastic interventions. This
assertion is supported by the remarkable growth in the
number of minimally invasive procedures performed.
Although the data do not demonstrate that minimally
invasive procedures are replacing surgical treatments, the
greater availability and choice of procedures appear to have
stimulated increased demand [3].
Minimally invasive procedures offer several beneﬁts.
They can be performed using local anesthesia, thus
reducing the risk of complications arising from general
anaesthesia, and do not require hospitalization. Because the
area of open tissue exposed is limited, the risk of serious
infections is consequently reduced. Given that many
patients seek augmentation for purely cosmetic purposes,
avoiding the hospital environment is clearly desirable.
Because the extent of trauma is less than with invasive
procedures, recovery times tend to be shorter, and the
patient can return to his or her normal routine far more
quickly. There also may be less requirement for pain
management, and patients usually can cope using over-the-
counter remedies.
Injectable products also can offer the advantages of
predictable, persistent correction through reproducible
implantation techniques providing the physician has a
thorough understanding of available products and their
indications/contraindications and limitations [26]. Patients
may ﬁnd the relatively rapid results offered by injectable
products inherently appealing, particularly if, as in the case
of autologous fat transfer or hyaluronic acid injections, a
natural material is implanted.
Fat transfer is the only minimally invasive treatment
option for body recontouring that has gained widespread
acceptance. In many ways, fat is an ideal ﬁller. It is non-
migratory, noncarcinogenic, and nonteratogenic, with a
low potential for abuse or misuse [26]. When used with the
correct technique, it also can provide long-lasting results.
However, the unpredictability of results, the uncertainties
surrounding longevity, and the requirement for donor
material may detract from the appeal of fat transfer. Donor
material, unlike fat transfer, is not required with other
injectable products, so these treatments may be more
suitable for those who do not wish to undergo, or are
unsuitable for, liposuction.
Although nonresorbable ﬁllers such as Aquamid and
Bio-Alcamid have shown promise, it is noteworthy that
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123neither product has gained widespread acceptance among
cosmetic surgeons. In two small pilot studies, the NASHA
gel product Macrolane demonstrated potential for use in
body recontouring and breast augmentation. An improved
product, Macrolane VRF, has recently received European
approval for breast enhancement, volume restoration, and
contouring of body surfaces. Macrolane VRF was devel-
oped in part as a direct response to concerns that arose in
these pilot studies, and no safety concerns have been raised
with the use of this gel formulation.
Macrolane VRF offers several distinct advantages over
permanent ﬁllers. Because it is a natural product, NASHA
gel has a good safety record when used cosmetically, and
although results last up to 18 months [37], the product is
nonpermanent, so long-term side effects are less likely than
with nonresorbable products. If necessary, Macrolane is
easily removable by aspiration. In addition, administration
is a minimally invasive procedure, resulting in less
downtime for patients and a shorter recovery time than
traditional surgical methods.
The use of Macrolane VRF for breast augmentation per-
haps holds the greatest promise. Because breasts are seen
simultaneouslyasamarkerofwomanhood,avisualsigniﬁer
of female sexuality synonymous with femininity, and
essential for nurturing infants, it is not surprising that a great
emphasis is placed on their appearance [33]. Furthermore,
the current feminine ideal is one of a body both slim and
large-breasted. Given that breasts are composed largely of
adipose tissue, few women can naturally achieve this ideal.
Perhaps for these reasons, breast augmentation currently is
themostwidelyperformedsurgicalcosmeticprocedure,and
its popularity is growing. Since 2000, the annual number of
performed procedures has risen by 55% [3].
Dissatisfaction with breast size and shape generally
motivates consideration of breast augmentation surgery
[40]. In one study, by the age of 18 years, more than one-
third of women expressed dissatisfaction with their breast
size [33]. Among this huge number of potentially dissat-
isﬁed women, some consider augmentation surgery, but
only a small proportion of these commit to undergo the
procedure. However, if a minimally invasive option were
to become widely available, it would offer women reluc-
tant to undertake the risks of surgery the opportunity to
achieve moderately increased breast size. It is therefore
noteworthy that although the experience of injecting
Macrolane into the female breast currently is limited, early
results are promising and warrant further investigation.
In conclusion, the expanding array of products and
techniques available has widened the scope of what can be
achieved by adding volume to areas of the body. Hyalu-
ronic acid has been speciﬁcally developed for minimally
invasive volume enhancement, including facial tissue
augmentation and breast enhancement. It is well tolerated,
with predictable long-lasting results. As patients continue
to opt for nonsurgical procedures that offer predictable
results, the development of minimally invasive products is
greatly welcomed.
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